Suppr超能文献

长期双膦酸盐治疗后,白种绝经后妇女中有无非典型股骨骨折的骨组织形态计量学差异。

Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy.

机构信息

Bone and Mineral Research Laboratory, Henry Ford Health, Detroit, MI 48202, USA.

Center for Mineral Metabolism and Clinical Research, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

出版信息

J Bone Miner Res. 2024 May 2;39(4):417-424. doi: 10.1093/jbmr/zjae018.

Abstract

Bone histomorphometric endpoints in transilial biopsies may be associated with an increased risk of atypical femoral fracture (AFF) in patients with osteoporosis who take antiresorptives, including bisphosphonates (BPs). One way to test this hypothesis is to evaluate bone histomorphometric endpoints in age-, gender-, and treatment time-matched patients who either had AFF or did not have AFF. In this study, we performed transiliac bone biopsies in 52 White postmenopausal women with (n = 20) and without (n = 32) AFFs, all of whom had been treated for osteoporosis continuously with alendronate for 4-17 yr. Despite the matched range of treatment duration (4-17 yr), AFF patients received alendronate for significantly longer time (10.7 yr) than non-AFF patients (8.0 yr) (P = .014). Bone histomorphometric endpoints reflecting microstructure and turnover were assessed in cancellous, intracortical, and endocortical envelopes from transilial biopsy specimens obtained from BP-treated patients 3-6 mo after AFF and from non-AFF patients with similar age-, gender-, and range of BP treatment duration. However, in both cancellous and intracortical envelopes, AFF patients had significantly lower wall thickness (W.Th) and higher osteoclast surface (Oc.S/BS) than non-AFF patients. In addition, AFF patients had significantly higher eroded surface (ES/BS) only in the intracortical envelope. None of the dynamic variables related to bone formation and turnover differed significantly between the groups. In conclusion, in the ilium of BP-treated patients with osteoporosis, AFF patients have lower thickness of superficial bone (lower W.Th) of the cancellous and cortical envelopes than non-AFF patients. AFF and non-AFF patients have a similar bone turnover rate in the ilium. Furthermore, in this population, as in previous work, AFF is more likely to occur in BP-treated patients with longer treatment duration.

摘要

经转子骨活检的骨组织形态计量学终点可能与接受抗吸收药物(包括双膦酸盐)治疗的骨质疏松症患者发生非典型股骨骨折(AFF)的风险增加相关。检验这一假说的一种方法是,评估在年龄、性别和治疗时间匹配的、发生 AFF 或未发生 AFF 的患者中经转子骨活检的骨组织形态计量学终点。在这项研究中,我们对 52 名白人绝经后女性进行了经转子骨活检,其中 20 名(n=20)患有 AFF,32 名(n=32)未患有 AFF,所有患者均连续接受阿仑膦酸钠治疗骨质疏松症 4-17 年。尽管治疗持续时间(4-17 年)相匹配,但 AFF 患者接受阿仑膦酸钠治疗的时间明显长于非 AFF 患者(10.7 年比 8.0 年)(P=0.014)。在发生 AFF 后 3-6 个月和年龄、性别及双膦酸盐治疗时间范围相匹配的非 AFF 患者中,评估了来自经转子骨活检样本的松质骨、皮质内和内皮质骨窗中反映微结构和转换的骨组织形态计量学终点。然而,在松质骨和皮质内骨窗中,AFF 患者的骨壁厚度(W.Th)明显低于非 AFF 患者,破骨细胞表面(Oc.S/BS)明显高于非 AFF 患者。此外,AFF 患者的侵蚀表面(ES/BS)仅在皮质内骨窗中明显更高。两组之间与骨形成和转换相关的任何动态变量均无显著差异。结论:在接受双膦酸盐治疗的骨质疏松症患者的髂骨中,与非 AFF 患者相比,AFF 患者的松质骨和皮质骨窗的浅层骨厚度(较低的 W.Th)较低。AFF 和非 AFF 患者的髂骨骨转换率相似。此外,在该人群中,与之前的研究结果一样,AFF 更可能发生在接受双膦酸盐治疗且治疗时间较长的患者中。

相似文献

2
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Cochrane Database Syst Rev. 2023 Jan 10;1(1):CD002010. doi: 10.1002/14651858.CD002010.pub5.
5
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD001155. doi: 10.1002/14651858.CD001155.pub3.
6
Long-term hormone therapy for perimenopausal and postmenopausal women.
Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
7
Treatment for osteoporosis in people with ß-thalassaemia.
Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2.
8
Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
J Bone Miner Res. 2021 Apr;36(4):644-653. doi: 10.1002/jbmr.4243. Epub 2021 Jan 28.
9
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Cochrane Database Syst Rev. 2022 May 3;5(5):CD004523. doi: 10.1002/14651858.CD004523.pub4.
10
Treatment for osteoporosis in people with beta-thalassaemia.
Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3.

引用本文的文献

1
Grading Pseudo Fractures.
Calcif Tissue Int. 2025 May 14;116(1):74. doi: 10.1007/s00223-025-01383-9.
2
Atypical femoral fracture in a patient with nutritional osteomalacia: a case report and literature review.
J Surg Case Rep. 2025 Jan 22;2025(1):rjaf020. doi: 10.1093/jscr/rjaf020. eCollection 2025 Jan.
4
Bone Loss in Diabetes Mellitus: Diaporosis.
Int J Mol Sci. 2024 Jul 2;25(13):7269. doi: 10.3390/ijms25137269.

本文引用的文献

1
Bone Turnover Markers: Basic Biology to Clinical Applications.
Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
2
Current concepts in the management of bisphosphonate associated atypical femoral fractures.
World J Orthop. 2021 Sep 18;12(9):660-671. doi: 10.5312/wjo.v12.i9.660.
3
The Genetics of Atypical Femur Fractures-a Systematic Review.
Curr Osteoporos Rep. 2021 Apr;19(2):123-130. doi: 10.1007/s11914-021-00658-y. Epub 2021 Feb 15.
4
Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
BMC Musculoskelet Disord. 2020 Dec 3;21(1):801. doi: 10.1186/s12891-020-03672-w.
5
Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women.
Calcif Tissue Int. 2020 Dec;107(6):543-550. doi: 10.1007/s00223-020-00748-6. Epub 2020 Aug 20.
6
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525.
8
Detection and management of atypical femur fractures.
Curr Opin Endocrinol Diabetes Obes. 2019 Dec;26(6):283-290. doi: 10.1097/MED.0000000000000505.
9
Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.
Osteoporos Int. 2019 Dec;30(12):2515-2520. doi: 10.1007/s00198-019-05112-5. Epub 2019 Sep 25.
10
Atypical femoral fractures from bisphosphonate in cancer patients - Review.
J Bone Oncol. 2019 Aug 22;18:100259. doi: 10.1016/j.jbo.2019.100259. eCollection 2019 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验